Rapport Therapeutics Quote - RAPP

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

12.69

Bid

12.10

Offer

14.60

Volume

83,781

12.52 Day's Range 13.52

12.0948 52 Week Range 29.74

Market Cap

464.155M

Previous Close

12.51

Open

12.74

Last Trade

447

12.69

(priorref)

Last Trade Time

Financial Volume

US$ 1,086,236

VWAP

12.9652

Average Volume (3m)

108,115

Shares Outstanding

36,576,457

Dividend Yield

PE Ratio

-13.38

Earnings Per Share (EPS)

-0.95

Revenue

Net Profit

-34.79M

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational sma... Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

New Castle, Delaware, USA

Founded

Rapport Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPP. The last closing price for Rapport Therapeutics was US$12.51. Over the last year, Rapport Therapeutics shares have traded in a share price range of US$ 12.0948 to US$ 29.74.

Rapport Therapeutics currently has 36,576,457 shares in issue. The market capitalisation of Rapport Therapeutics is US$457.57 million. Rapport Therapeutics has a price to earnings ratio (PE ratio) of -13.38.

Form 8-K - Current report

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the...

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted...

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-3.79	-22.9975728155	16.48	16.9	12.0948	144256	13.91041164	CS
4	-4.88	-27.7746158224	17.57	20.22	12.0948	118958	16.69755422	CS
12	-12.22	-49.0566037736	24.91	28.005	12.0948	108115	20.10669184	CS
26	-15.39	-54.8076923077	28.08	29.74	12.0948	132052	20.86074424	CS
52	-5.31	-29.5	18	29.74	12.0948	151806	21.58478651	CS
156	-5.31	-29.5	18	29.74	12.0948	151806	21.58478651	CS
260	-5.31	-29.5	18	29.74	12.0948	151806	21.58478651	CS

RAPP - Frequently Asked Questions (FAQ)

What is the current Rapport Therapeutics share price?

The current share price of Rapport Therapeutics is US$ 12.69

How many Rapport Therapeutics shares are in issue?

Rapport Therapeutics has 36,576,457 shares in issue

What is the market cap of Rapport Therapeutics?

The market capitalisation of Rapport Therapeutics is USD 457.57M

What is the 1 year trading range for Rapport Therapeutics share price?

Rapport Therapeutics has traded in the range of US$ 12.0948 to US$ 29.74 during the past year

What is the PE ratio of Rapport Therapeutics?

The price to earnings ratio of Rapport Therapeutics is -13.38

What is the reporting currency for Rapport Therapeutics?

Rapport Therapeutics reports financial results in USD

What is the latest annual profit for Rapport Therapeutics?

The latest annual profit of Rapport Therapeutics is USD -34.79M

What is the registered address of Rapport Therapeutics?

The registered address for Rapport Therapeutics is 1209 ORANGE STREET, IN THE CITY OF WILMINGTON, NEW CASTLE, DELAWARE, 19801

Which industry sector does Rapport Therapeutics operate in?

Rapport Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M